View source for 18279004. LIPOSOMAL FORMULATIONS OF BORONIC ACID CONTAINING ACTIVE AGENTS simplified abstract (OHIO STATE INNOVATION FOUNDATION)

=LIPOSOMAL FORMULATIONS OF BORONIC ACID CONTAINING ACTIVE AGENTS=


==Organization Name==

[[:Category:OHIO STATE INNOVATION FOUNDATION|OHIO STATE INNOVATION FOUNDATION]]


[[Category:OHIO STATE INNOVATION FOUNDATION]]

==Inventor(s)==

[[:Category:Robert Lee of Lewis Center OH (US)|Robert Lee of Lewis Center OH (US)]][[Category:Robert Lee of Lewis Center OH (US)]]

==LIPOSOMAL FORMULATIONS OF BORONIC ACID CONTAINING ACTIVE AGENTS - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18279004 titled 'LIPOSOMAL FORMULATIONS OF BORONIC ACID CONTAINING ACTIVE AGENTS

==Simplified Explanation==

The patent application describes a liposomal formulation for the improved delivery of boronic acid esters of boronic acid therapeutic agents. The formulation includes liposomes formed from a vesicle-forming lipid and a capturing agent-active agent complex encapsulated in the liposomes.

* Liposomal formulation for improved delivery of boronic acid esters of boronic acid therapeutic agents
* Liposomes formed from a vesicle-forming lipid
* Capturing agent-active agent complex encapsulated in the liposomes

== Potential Applications ==
The technology could be applied in the pharmaceutical industry for the targeted delivery of boronic acid therapeutic agents, potentially improving their efficacy and reducing side effects.

== Problems Solved ==
1. Enhanced delivery of boronic acid esters of boronic acid therapeutic agents
2. Targeted delivery to specific cells or tissues

== Benefits ==
1. Improved efficacy of boronic acid therapeutic agents
2. Reduced side effects
3. Targeted delivery for better treatment outcomes

== Potential Commercial Applications ==
"Targeted Delivery of Boronic Acid Therapeutic Agents Using Liposomal Formulation"

== Possible Prior Art ==
There may be prior art related to liposomal formulations for drug delivery, especially in the field of cancer treatment where targeted delivery is crucial.

== Unanswered Questions ==

=== How does the liposomal formulation compare to other drug delivery methods in terms of efficiency and safety? ===
The article does not provide a direct comparison with other drug delivery methods, leaving a gap in understanding the advantages of this specific formulation.

=== Are there any limitations or challenges in scaling up the production of this liposomal formulation for commercial use? ===
The scalability and production challenges of this technology are not addressed in the article, leaving room for further investigation into its practical applications.


==Original Abstract Submitted==

Described are liposomal formulation for the improved delivery of boronic acid esters of boronic acid therapeutic agents. The liposomal formulation can include (i) liposomes formed from a vesicle-forming lipid; and (ii) a capturing agent-active agent complex encapsulated in the liposomes.



[[Category:A61K38/05]]
[[Category:A61K9/127]]
[[Category:A61P35/00]]